BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a California-based global biotechnology company, announced on Wednesday that it has named Alexander Hardy as its new president and chief executive officer.
Hardy is to succeed Jean-Jacques Bienaime, who will retire as chairman and CEO effective 1 December 2023.
Hardy has over 30 years of experience in the global healthcare and biotechnology industries. He has served as the CEO of Genentech and in various senior roles at Roche and in leadership roles at Novartis, PathoGenesis and GSK.
enGene names new chief financial officer and head of Business Development
The American Board of Medical Specialties names new members of the board of directors
MedGenome names new Advisory Board chairman
MentalHealth.com names new Dr Jesse Hanson as new clinical director
Element Biosciences names new director
BD names new executive vice president and chief medical officer
Fuse Oncology names new chief technology officer
Halia Therapeutics names new vice president Regulatory Affairs and new senior medical director
Rivus Pharmaceuticals names new chief medical officer
K36 Therapeutics names new chief medical officer
Kyverna Therapeutics' fifth KYV-101 Investigational New Drug application receives US FDA approval
Nereid Therapeutics names new president and chief executive officer